Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02945969 · ClinicalTrials.gov registry record · Phase 3
Sodium Lowering and Urinary Protein Reduction Trial
A Phase 3 study, sponsored by Tulane University School of Public Health and Tropical Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 151
- Enrollment target
NCT02945969: Completed Phase 3 study, sponsored by Tulane University School of Public Health and Tropical Medicine.
NCT02945969 is a Phase 3 study that has completed, run by Tulane University School of Public Health and Tropical Medicine. The registered enrollment target is 151 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02945969, a Phase 3 study, has completed, sponsored by Tulane University School of Public Health and Tropical Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 151 participants
- Enrollment target
Study Summary
The proposed randomized controlled trial will test the effect of dietary sodium reduction on albuminuria in patients with proteinuric chronic kidney disease. Results from this study will clarify the role of dietary sodium reduction in management of patients with proteinuric chronic kidney disease and its potential to halt the progression of chronic kidney disease.
Interventions
- BEHAVIORAL Low Sodium Diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2016-11 |
| Est. Completion | 2021-01 |
| Phase | Phase 3 |
What the finished NCT02945969 record still lists
NCT02945969 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which Low Sodium Diet is the first listed.
NCT02945969 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02945969 about?
NCT02945969 is a clinical study titled "Sodium Lowering and Urinary Protein Reduction Trial". The proposed randomized controlled trial will test the effect of dietary sodium reduction on albuminuria in patients with proteinuric chronic kidney disease. Results from this study will clarify the role of dietary sodium reduction in management of patients with proteinuric chronic kidney disease an...
What is the current status of trial NCT02945969?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 151 participants. The study started on 2016-11. Estimated completion is 2021-01.
What interventions are being tested in trial NCT02945969?
The interventions under investigation include: Low Sodium Diet (BEHAVIORAL).
Who is sponsoring clinical trial NCT02945969?
This trial is sponsored by Tulane University School of Public Health and Tropical Medicine, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02945969's enrollment target sits among peer trials
151 1517th of 2000 higher than 482 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia